Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,737 total articles
JPMorgan Chase (JPM) looks attractive as a long trade under $300. The bank trades at roughly 14x earnings with a 2%+ dividend yield, a healthy ROE and a large buyback/dividend capacity. Technicals show the name is oversold and below key moving averages, offering a defined entry with a clear stop and a realistic target near the 52-week high. This is…
Fair Isaac (FICO) reported earnings that underscore durable margins, strong free cash flow and an advantaged position in fraud, scoring and decisioning. The market sold off aggressively; that gap creates a low-risk entry for patient long-term traders. We upgrade our rating and lay out a concrete trade plan with a clear stop and targets.
Nexa Resources (NEXA) is a Latin American zinc miner and smelter trading at a modest multiple (PE ~11.7, PB ~1.55) with a market cap of $1.56B. The company’s integrated mining + smelting footprint gives it leverage to a cyclical recovery and operational improvements that can translate into visible free cash flow. We initiate an actionable trade: bu…
APA trades at a single-digit P/E and sub-2x P/B while generating roughly $1.8B of free cash flow. With improving momentum, a maintained $0.25 quarterly dividend and multiple near-term operational catalysts, I see asymmetric upside into $40 over the next 180 trading days with a tight stop at $28.
Byrna Technologies reported $118.1M in revenue for FY2025 (up 38% YoY) and remains a small-cap growth story trading near its 52-week low. With expanding retail distribution, production capacity increases, a planned marketing push and a still-modest valuation (market cap ~ $234M; EV/EBITDA ~ 15.8), there is a reasonable asymmetric opportunity for pa…
TSMC (TSM) has pulled back into the low $300s while demand from high-performance computing remains strong. Fundamentals and market share justify buying on a disciplined dip; this trade targets a retest of the 52-week high with a clearly defined stop.
Western Midstream (WES) offers an attractive entry for income-oriented investors: a 9%+ yield, strong free cash flow, and near-term catalysts in produced-water and data-center driven energy demand. Valuation is reasonable by cash-flow metrics and the balance sheet shows manageable liquidity. This trade idea outlines an actionable entry, stop, and t…
Unusual Machines (UMAC) is trading on a clear sentiment catalyst: accelerating revenue, a large cash balance and expanding addressable market from U.S. defense and regulatory shifts. The setup is actionable as a momentum swing trade while the company's fundamentals suggest a longer runway — but valuation is rich and execution risk is real. We outli…
Phase 3 data show ralinepag cuts clinical worsening by 55% and boosts improvement odds by 47%. With an NDA planned by mid-2026, a strong balance sheet, no debt and robust free cash flow position United Therapeutics to defend market share and valuation. We upgrade to a long with a clear entry, stop and target for a 180-trading-day horizon.
Microsoft is pulling back from recent highs but the core business and AI-driven growth vectors remain intact. With $77B of trailing free cash flow, a $3.01T market cap, low leverage and improving technical breadth, we upgrade to Buy and recommend a tactical swing entry at $405 with a $460 target and $385 stop. The trade is driven by Azure/AI adopti…
Telephone and Data Systems preferred shares currently offer an attractive income entry: trading below likely redemption value, supported by a strengthened balance sheet after the UScellular sale, and with upside if rates stabilize. This trade targets capture of the discount to redemption and dividend carry over a mid-term horizon while keeping down…
Nebius is executing a bold buildout of AI data center capacity backed by anchored customer commitments and hefty institutional interest. With a $20+ billion backlog, a $3 billion contract with Meta and management s plan to scale to $7-9 billion in annualized revenue by year-end 2026, I m upgrading NBIS to a buy and initiating a long trade with a cl…
NICE Ltd. is trading well below its 52-week high but shows accelerating AI ARR, mid-teens cloud growth, and attractive valuation metrics. We upgrade to Buy and lay out a clear entry at $122.59, a stop at $110.00 and a $155.00 target tied to continued cloud adoption and product-led AI expansion.
Sanmina trades like a mid-cap manufacturing play that already has a seat at the table for cloud AI hardware after its $3B ZT Systems purchase. The stock sold off on cautious guidance, leaving a chance to buy a predictable cash-generator with a clear operational path to capture AMD-related server demand. This trade idea lays out an actionable entry …
CoreWeave's growth story is real: $5.1B in revenue in 2025 and a $66.8B backlog. But the company is capital hungry, levered, and unprofitable. With $30-35B of capex guidance for 2026 and rising interest expense, the path to cash generation looks riskier than the headline backlog implies. This trade idea lays out a mid-term short for disciplined tra…
Lumentum (LITE) trades at roughly $682 after a volatile stretch and presents a tactical long opportunity as optical demand from AI data centers accelerates. The thesis leans on a strategic Nvidia partnership, sizable market growth forecasts for optical interconnects, and improving technicals, but the name is richly valued and carries operational an…
Repsol’s ADR is showing bullish momentum after the company's Capital Markets Day, underpinned by new renewable-project contracts and constructive technicals. We view REPYY as a strong buy for swing-oriented traders, with an entry at $24.50, a stop at $22.00 and a primary target of $29.00 over a mid-term 45 trading day horizon. The trade balances up…
Sherwin-Williams has weathered a soft construction backdrop and still delivers strong cash generation and dividend growth. With shares trading near $330 and technicals showing short-term oversold conditions, we upgrade to a buy and lay out an actionable swing trade: entry $330.46, stop $305.00, target $380.00 over ~45 trading days. Risks include hi…
Lincoln National (LNC) offers a rare income-first equity opportunity: a roughly 6.5% yield, P/E below 6, and tangible upside to $40 if annuity and fee trends normalize. The balance sheet and FCF profile require respect, but the stock's valuation and recent operational momentum make a disciplined long trade attractive for income-oriented, medium-ris…
ZIM is trading near $28.93 while Hapag-Lloyd has agreed to acquire the company for $35 in cash. The spread reflects regulatory and execution risk rather than fundamental value. For investors comfortable with deal risk, a long arbitrage from $28.93 into $35 offers a defined upside and a manageable stop if regulatory or financing concerns re-emerge.
Advanced Micro Devices is uniquely positioned to benefit from the surge in 'agentic' AI - autonomous agents that combine models, software and inference at scale. With a clean balance sheet, accelerating data-center traction and a landmark partnership with Meta that CEO Lisa Su expects to become a triple-digit billion dollar deal, AMD looks worth an…
Aquestive's Anaphylm clinical readouts and renewed investor engagement suggest the company is closer to resolving prior FDA deficiencies. The stock at $4.25 offers a risk-reward setup if management can translate recent data and conference activity into constructive FDA dialogue. This trade idea outlines a mid-term long with an entry at $4.20, a sto…
Riley Exploration Permian (REPX) is trading at a low P/E and attractive dividend yield while generating solid free cash flow and returns on capital. Operational catalysts tied to Permian acreage development and a push into 2026 production growth justify a long trade: entry at $32.05, stop at $27.00, target $44.00 over a 180-trading-day horizon.
Immunome (IMNM) is a clinical-stage antibody developer trading at a $2.4B+ market cap despite negative earnings and a large negative free cash flow. If the market is right about an upcoming NDA-related run, shares have room to move toward the analyst consensus near $30. This trade pairs a tactical long entry at $22.00 with a $30.00 target and tight…
Cigna has delivered repeated earnings beats and raised dividends, yet shares have sold off amid PBM scrutiny and an active short interest. Fundamentals - including $8.4B free cash flow and a sub-12x P/E - argue the stock is cheap enough for a tactical long. This trade targets a mid-term rebound while respecting regulatory and margin risks.
